Menu
Search
|

Menu

Close
X

Abeona Therapeutics Inc ABEO.OQ (NASDAQ Stock Exchange Capital Market)

10.40 USD
-- (--)
As of Oct 12
chart
Previous Close 10.40
Open --
Volume --
3m Avg Volume 181,106
Today’s High --
Today’s Low --
52 Week High 22.00
52 Week Low 9.68
Shares Outstanding (mil) 40.29
Market Capitalization (mil) 713.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
1
FY16
1
FY15
1
EPS (USD)
FY18
-0.427
FY17
-0.653
FY16
-0.637
FY15
-0.523
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
845.89
5.74
Price to Book (MRQ)
vs sector
8.00
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
0.00
16.89
LT Debt to Equity (MRQ)
vs sector
0.00
12.55
Return on Investment (TTM)
vs sector
-29.33
14.60
Return on Equity (TTM)
vs sector
-30.75
16.33

EXECUTIVE LEADERSHIP

Steven Rouhandeh
Executive Chairman of the Board, Since 2015
Salary: $386,000.00
Bonus: $154,000.00
Timothy Miller
President, Chief Scientific Officer, Since 2018
Salary: $375,000.00
Bonus: $150,000.00
Frank Thiel
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Stephen Thompson
Senior Vice President - Finance and Administration, Chief Accounting Officer, Treasurer, Secretary, Since 2015
Salary: $154,080.00
Bonus: --
David Nowotnik
Senior Vice President - Research and Development, Since 2016
Salary: $129,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3333 Lee Pkwy Ste 600
DALLAS   TX   75219-5117

Phone: +1214.9055100

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

SPONSORED STORIES